Omnicell [OMCL] vs 10x Genomics [TXG] Detailed Stock Comparison

Omnicell

NASDAQ
Loading...

10x Genomics

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Omnicell wins in 12 metrics, 10x Genomics wins in 6 metrics, with 0 ties. Omnicell appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricOmnicell10x GenomicsBetter
P/E Ratio (TTM)61.90-8.5510x Genomics
Price-to-Book Ratio1.142.05Omnicell
Debt-to-Equity Ratio30.4211.2210x Genomics
PEG Ratio1.240.0510x Genomics
EV/EBITDA19.00-11.0710x Genomics
Profit Margin (TTM)2.01%-13.13%Omnicell
Operating Margin (TTM)2.80%-2.63%Omnicell
EBITDA Margin (TTM)2.80%N/AN/A
Return on Equity1.87%-11.30%Omnicell
Return on Assets (TTM)0.49%-9.45%Omnicell
Free Cash Flow (TTM)$134.93M$-6.73MOmnicell
1-Year Return-28.39%-22.26%10x Genomics
Price-to-Sales Ratio (TTM)1.242.46Omnicell
Enterprise Value$1.41B$1.23BOmnicell
EV/Revenue Ratio1.221.90Omnicell
Gross Profit Margin (TTM)43.94%72.34%10x Genomics
Revenue per Share (TTM)$25$5Omnicell
Earnings per Share (Diluted)$0.50$-0.70Omnicell
Beta (Stock Volatility)0.882.05Omnicell
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Omnicell vs 10x Genomics Stock Performance Analysis

Loading Price Chart...

Omnicell
10x Genomics
Omnicell Stock Overview | 10x Genomics Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Omnicell-1.39%0.59%-5.60%5.53%-3.42%-31.14%
10x Genomics-0.86%11.46%-9.26%6.04%66.75%-10.92%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Omnicell-28.39%-58.34%-62.99%0.36%126.07%225.72%
10x Genomics-22.26%-50.59%-92.28%-75.82%-75.82%-75.82%

News Based Sentiment: Omnicell vs 10x Genomics

Omnicell

News based Sentiment: MIXED

October brought a blend of positive and negative developments for Omnicell, including insider buying, a 'Buy' rating, but also recent price declines and a significant year-over-year loss in market capitalization. The upcoming Q3 earnings report on October 29th is a key catalyst that will shape the investment narrative.

View Omnicell News Sentiment Analysis

10x Genomics

News based Sentiment: MIXED

October brought a strong Q3 earnings beat and positive analyst revisions for 10x Genomics, but these were tempered by a negative full-year EPS forecast and mixed technical indicators. This creates a complex investment picture with both opportunities and risks, making it a significant month for the company.

View 10x Genomics News Sentiment Analysis

Performance & Financial Health Analysis: Omnicell vs 10x Genomics

MetricOMCLTXG
Market Information
Market Cap i$1.46B$1.59B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i350,2932,746,660
90 Day Avg. Volume i488,7782,469,420
Last Close$30.52$12.64
52 Week Range$22.66 - $55.75$6.78 - $20.92
% from 52W High-45.26%-39.58%
All-Time High$187.29 (Nov 22, 2021)$208.99 (Jun 28, 2021)
% from All-Time High-83.70%-93.95%
Growth Metrics
Quarterly Revenue Growth0.05%0.13%
Quarterly Earnings Growth0.51%0.13%
Financial Health
Profit Margin (TTM) i0.02%-0.13%
Operating Margin (TTM) i0.03%-0.03%
Return on Equity (TTM) i0.02%-0.11%
Debt to Equity (MRQ) i30.4211.22
Cash & Liquidity
Book Value per Share (MRQ)$27.22$6.21
Cash per Share (MRQ)$8.69$3.59
Operating Cash Flow (TTM) i$147.75M$66.95M
Levered Free Cash Flow (TTM) i$85.81M$58.22M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Omnicell vs 10x Genomics

MetricOMCLTXG
Price Ratios
P/E Ratio (TTM) i61.90-8.55
Forward P/E i17.19-10.45
PEG Ratio i1.240.05
Price to Sales (TTM) i1.242.46
Price to Book (MRQ) i1.142.05
Market Capitalization
Market Capitalization i$1.46B$1.59B
Enterprise Value i$1.41B$1.23B
Enterprise Value Metrics
Enterprise to Revenue i1.221.90
Enterprise to EBITDA i19.00-11.07
Risk & Other Metrics
Beta i0.882.05
Book Value per Share (MRQ) i$27.22$6.21

Financial Statements Comparison: Omnicell vs 10x Genomics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)OMCLTXG
Revenue/Sales i$290.56M$154.88M
Cost of Goods Sold i$162.88M$49.44M
Gross Profit i$127.68M$105.45M
Research & Development i$21.57M$64.25M
Operating Income (EBIT) i$8.12M$-48.53M
EBITDA i$29.77M$-32.89M
Pre-Tax Income i$10.45M$-33.51M
Income Tax i$4.81M$852,000
Net Income (Profit) i$5.64M$-34.36M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)OMCLTXG
Cash & Equivalents i$386.83M$377.06M
Total Current Assets i$839.67M$579.73M
Total Current Liabilities i$607.53M$107.90M
Long-Term Debt i$199.72M$70.63M
Total Shareholders Equity i$1.26B$706.90M
Retained Earnings i$375.87M$-1.50B
Property, Plant & Equipment i$130.63M$55.58M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)OMCLTXG
Operating Cash Flow i$28.34M$35.44M
Capital Expenditures i$-11.17M$-1.89M
Free Cash Flow i$10.19M$32.46M
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricOMCLTXG
Shares Short i1.97M17.35M
Short Ratio i3.807.58
Short % of Float i0.06%0.22%
Average Daily Volume (10 Day) i350,2932,746,660
Average Daily Volume (90 Day) i488,7782,469,420
Shares Outstanding i46.38M122.29M
Float Shares i44.82M109.33M
% Held by Insiders i0.02%0.02%
% Held by Institutions i1.05%1.05%

Dividend Analysis & Yield Comparison: Omnicell vs 10x Genomics

MetricOMCLTXG
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A